This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Food and Drug Administration data shows that agency staffers have not returned to roughly 2,000 pharmaceuticalmanufacturing firms to conduct surveillance inspections since before the pandemic, raising the risks of contamination and other issues in drugs used by millions of Americans. An analysis of U.S.
In a recent move, Kashmik launched Dapagliflozin under the DAPNEC brand in the anti-diabetic segment. Commenting on these developments, Nilesh Patel, Managing Director of Kashmik Formulation, said, “At Kashmik, we are focused on building scalable, efficient, and globally competitive pharmaceuticalmanufacturing capabilities.
Accretion Pharmaceuticals, an Ahmedabad-headquartered pharmaceuticalsmanufacturer, announced that its initial public offering (IPO) will open for subscription on Wednesday, May 14, 2025. The anchor portion will be opened on Tuesday, May 13, 2025, and the issue will conclude on Friday, May 16, 2025.
As the adoption of biologics rises, demand for home healthcare grows, and conditions like diabetes and autoimmune disorders become more prevalent, self-injectables are here to stay.
By diversifying their approach, manufacturers aim to preserve GTN and ensure long-term business sustainability. The GLP-1 Revolution: Balancing Innovation, Access, and Societal Impact The rapid growth of GLP-1 receptor agonists (GLP-1s) is reshaping treatment paradigms for type 2 diabetes and obesity.
What are the top 3 trends that defined pharma manufacturing in India and globally in 2024? In 2024, the pharmaceuticalmanufacturing landscape underwent transformative changes, driven by technological innovations, regulatory adaptations, and evolving global demands.
Novo Nordisk’s Denmark manufacturing facilities Currently, Novo Nordisk’s Kalundborg production facilities manufacture products for treating obesity and diabetes as well as several biopharmaceutical products, employing around 4,400 employees. In June 2023, the company announced its plans to invest €2.1
The findings point to a “threat to environmental and global health,” say the scientists, who found that paracetamol, antibiotics epilepsy drug carbamazepine, metformin for diabetes and other compounds like caffeine and nicotine were found in samples from around the world – including in Antarctica.
Lilly chair and CEO Dave Ricks said: “Through these new facilities, Hoosiers [workers from the state of Indiana] will make life-changing medicines that patients around the world need to address serious health challenges, including diabetes and cancer. “We’re Last year, the company committed to providing $42.5m
Eylea is approved in four indications in Europe: the treatment of ‘wet’ age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV).
SDoH can influence diabetes risk and management, and access to healthcare can also affect disease management and progression. One study dove into whether annual income influenced choice in GLP-1 RA therapy for patients with Type 2 Diabetes. medication accessibility), especially in cases where there are multiple in-class agents.”
Additionally, in October, EPR shared Phase III trial data for the type 1 diabetes treatment TZIELD (Teplizumab), which suggested that the medicine could slow disease progression. The year 2023 also brought much advancement in the Alzheimer’s space for the pharmaceutical industry.
The Fund – set up as a public-private partnership by the International Federation of PharmaceuticalManufacturers and Associations (IFPMA) – started life with $1 billion earmarked to support companies trying to develop antibiotics that can be used to replace those that have started to lose their effectiveness.
A respiratory platform similar to the diabetes one, the Digital Health Solution is yet another future-looking inclusion in the Chiesi plan. Having built a considerable reputation via its immunotherapies and respiratory products, Chiesi’s first rare disease drug is zampilimab, a novel monoclonal antibody for fibrotic lung diseases.
facility for manufacturing biologics in his presentation. —a combination of AI, IoT, and Digital Twins—for pharmaceuticalmanufacturers. Dr. Samir discussed Agilent's new Agilent University idea as well as how the company is creating analytical solutions to enable the smart manufacture of biologics.
The Advanced Technologies Lab will help industry and regulators accelerate the adoption of new technologies that help to mitigate supply chain risks and, where appropriate, establish guidance that supports regulatory predictability, process efficiencies, and faster time to market, all of which can strengthen domestic manufacturing capabilities.
We can also see from this excerpt that at the scale of large PBMs, formulary strategies are also a piece of negotiating leverage to obtain rebates and fees from pharmaceuticalmanufacturers. However, once negotiations are completed and rebate contracted executed, rebates can be cut off punitively by pharmaceuticalmanufacturers.
The pandemic effectively shut down supply chain paths overnight, and as a result, pharmaceuticalmanufacturers have faced delays and bottlenecks, which have caused drug shortages in healthcare systems. A break in the supply chain could have enormous implications for millions of people suffering from these conditions.
Sanofi has signed definitive agreements with Adragos Pharmaceutical, a German contract development and manufacturing organisation (CDMO), for the sale of its pharmaceuticalmanufacturing site in Kawagoe, Japan. The French pharmaceutical company will also enter into a long-term supply agreement with the CDMO.
For submission consideration, manufacturers can petition the FDA for ANDA status if the requested change does not require safety or effectiveness studies. It is basically an essential copy, and the pharmaceuticalmanufacturer has to show bioequivalence to the reference product,” Soefje said. “If
This involves close coordination with specialty pharmacies, infusion services, retail pharmacies, pharmaceuticalmanufacturers, medication access programs, and industry representatives. In many cases, the pharmacist resolves the issue independently, escalating to the provider only when necessary.
Biologics and antibiotics could be worst hit due to their energy-intensive manufacturing processes, along with the supply of glass vials and syringes disrupting the supply chain. Moreover, US Pharmacopeia issued the first-ever Medicine Supply Map to find and quantify risks in upstream pharmaceutical supply chains across the country.
Juno Pharmaceuticals Canada has purchased Omega Laboratories, a specialist injectable pharmaceuticalmanufacturer in Canada, for an undisclosed sum. The merged entity represents one of the biggest specialist generic injectable operations in Canada with local manufacturing facilities.
Since manufacturers know the precise quality specifications, standards help make the approval process for generic medicines more efficient. By enabling a multi-manufacturer environment, USP standards have helped increase the availability of medicines to treat cardiovascular disease, cancer, diabetes, mental health and many other conditions.
5 The Most Significant Driver of Health Care Spend Isn’t Drugs—It Isn’t Even Close Pharmaceuticalmanufacturers are a frequent punching bag for politicians, mostly because they are easy targets, and they tend to have more visible out-of-pocket exposure.
3,4 How this pricing model will be implemented and whether pharmaceuticalmanufacturers will be able to meet the expectations of the 2025 executive order, if upheld, is uncertain. The order states that if manufacturers are unable to meet the 30-day deadline, the secretary of the Department of Health and Human Services, Robert F.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content